Ann: Outcomes of DMX-200 pre-IND meeting with the FDA-DXB.AX, page-22

That's great RT- glad you've had recent success. Still strongly believe we will see a move this Quarter. The interim results will be based on ~50% of patients enrolled in part A which is dosing over 24 weeks. This is a significant dosing period to show efficacy. If there isn't any at the interim stage this Quarter when reported, then it's pretty unlikely they will have much more luck next year. Having said that- I can only reiterate the significance of trial patients continuing on the drug after the trial.. it's a smoking gun! Might be worth putting one of those bags back in DXB? The buying has been quite strong over the last 1-2 weeks. People getting set. As always, DYOR.